AMRN — Amarin Corporation plc

Amarin Corporation (AMRN) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total net revenue for Q1 2026 was $45.1 million, up from $42 million in Q1 2025.
• U.S. revenue remained stable year-over-year, while European revenue rose significantly to $4.9 million, a 113% increase from Q4 2025.
• Operating loss narrowed to $11.3 million from $16.8 million in Q1 2025; excluding restructuring charges, the operating loss was $8 million.
• Cash balance increased to $308 million, with positive cash flow from operations of $6.4 million for the second consecutive quarter.
• Total operating expenses decreased by 31% to $29.1 million, with SG&A expenses down 42% to 47% of total net sales.

2. Strategic Updates and Business Highlights:

• Amarin has completed its global restructuring aimed at achieving $70 million in annual operating expense savings by June 30, 2026.
• The company is focused on expanding the global market for VASCEPA through a partnered international commercial strategy, particularly with Recordati in Europe.
• VASCEPA continues to lead the U.S. market with a 48% share, up from 42% year-over-year, despite pressures from generic competition.
• New clinical guidelines from major medical associations have reinforced the importance of addressing triglyceride levels, positioning VASCEPA favorably in the treatment landscape.

3. Forward Guidance and Outlook:

• Amarin expects to maintain positive cash flow throughout 2026 and anticipates continued growth in both U.S. and international markets.
• The company plans to sustain exclusive contracts with key payers in the U.S. through the end of 2026, which is crucial for revenue stability.
• Future cash returns to shareholders are being considered, with discussions ongoing about potential buybacks or other value-enhancing strategies.

4. Bad News, Challenges, or Points of Concern:

• The U.S. revenue is under pressure from generic competition, and while the company has regained exclusive contracts, pricing pressures remain a concern.
• The transition to a partnered sales model in Europe may lead to revenue variability based on market demand and partnership agreements.
• The company’s reliance on maintaining exclusive contracts poses a risk if market dynamics change unexpectedly.

5. Notable Q&A Insights:

• Management expressed confidence in sustaining positive cash flow beyond 2026, contingent on retaining exclusive payer contracts.
• There is a cautious optimism regarding the impact of updated clinical guidelines on physician prescribing behavior, although it may take time to translate into sales growth.
• The decision to launch an authorized generic will depend on market conditions; currently, the company is focused on maintaining its profitable branded business.
• Amarin is seeing early positive demand growth in international markets, but specific milestone payments from partnerships have not been detailed.

Overall, Amarin demonstrated solid financial performance in Q1 2026, with strategic initiatives aimed at enhancing its market position, particularly in Europe. However, challenges from competition and pricing pressures in the U.S. market remain critical areas to monitor.